Wells Fargo Raises Taysha Gene Therapies Target Price to $8.00 Amid 'Overweight' Rating

Wells Fargo has raised its target price for Taysha Gene Therapies (TSHA) from $7.50 to $8.00, a 6.67% increase, while maintaining an "Overweight" rating. This move follows several analyst updates, including Chardan Capital's "Buy" rating and B of A Securities' initiation of coverage with a "Buy" rating. Taysha Gene Therapies is focused on developing gene therapies for CNS diseases, with its product pipeline including TSHA-102 for Rett syndrome. The average target price for TSHA is $8.04, with a high estimate of $13.00 and a low estimate of $5.00.

In a significant move for Taysha Gene Therapies (NASDAQ:TSHA), Wells Fargo has recently increased its target price from $7.50 to $8.00, representing a 6.67% boost. This update follows a series of analyst revisions that have shown increased optimism for the company's prospects [1].

Wells Fargo's new target price aligns with the broader trend of analysts raising their expectations for TSHA. Chardan Capital, for instance, has upgraded its rating to "Buy" with a target price of $10.00, while B of A Securities initiated coverage with a "Buy" rating and a target price of $8.00 [1]. These moves reflect a growing consensus among analysts that Taysha Gene Therapies is undervalued and poised for growth.

Taysha Gene Therapies focuses on developing gene therapies for central nervous system (CNS) diseases, with a pipeline that includes TSHA-102 for the treatment of Rett syndrome. The company's pipeline is diverse and includes therapies for conditions such as giant axonal neuropathy, CLN7 disease, CLN1 disease, and others [2].

The average target price for TSHA stands at $8.04, with a high estimate of $13.00 and a low estimate of $5.00. This range indicates a wide spread of analyst opinions but also underscores the potential for significant upside [1].

Taysha Gene Therapies' recent earnings report showed a loss of $0.09 per share, missing the consensus estimate of $0.07. Despite this, the company's debt-to-equity ratio of 0.77 and quick ratio of 5.35 suggest a strong balance sheet, which could support future growth [1].

The company's insider activity and institutional ownership also indicate a level of confidence in its prospects. Major shareholder Paul B. Manning increased his holdings by 35.86% in a recent transaction, while institutional investors hold 77.70% of the company's stock [1].

As analysts continue to raise their target prices and ratings, investors may want to closely monitor Taysha Gene Therapies' progress in developing its gene therapy pipeline and its ability to execute on its business strategy.

References:
[1] https://www.marketbeat.com/instant-alerts/taysha-gene-therapies-nasdaqtsha-price-target-raised-to-1000-2025-08-12/
[2] https://www.benzinga.com/insights/analyst-ratings/25/08/47088824/a-glimpse-into-the-expert-outlook-on-taysha-gene-therapies-through-11-analysts